Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors.

Kanomata N, Yamaguchi R, Kurebayashi J, Moriya T.

Med Mol Morphol. 2019 May 28. doi: 10.1007/s00795-019-00226-5. [Epub ahead of print]

PMID:
31139940
2.

CD1d- and PJA2-related immune microenvironment differs between invasive breast carcinomas with and without a micropapillary feature.

Kanomata N, Kurebayashi J, Koike Y, Yamaguchi R, Moriya T.

BMC Cancer. 2019 Jan 16;19(1):76. doi: 10.1186/s12885-018-5221-9.

3.

Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.

Kanomata N, Kurebayashi J, Moriya T.

Med Mol Morphol. 2019 Jun;52(2):106-113. doi: 10.1007/s00795-018-0208-9. Epub 2018 Oct 13.

PMID:
30317526
4.

[A Case Report of Surgery and Chemotherapy for a Patient with Rapidly Progressing Breast Cancer during Pregnancy].

Hazama Y, Nakai Y, Sugawara S, Nomura T, Matsumoto K, Matsumoto R, Sugihara M, Ishida T, Murata S, Murata T, Nakamura T, Moriya T, Kurebayashi J, Shimoya K.

Gan To Kagaku Ryoho. 2018 May;45(5):847-850. Japanese.

PMID:
30026449
5.

Comprehensive immunohistochemical analyses on expression levels of hedgehog signaling molecules in breast cancers.

Kurebayashi J, Kanomata N, Koike Y, Ohta Y, Saitoh W, Kishino E.

Breast Cancer. 2018 Nov;25(6):759-767. doi: 10.1007/s12282-018-0884-2. Epub 2018 Jun 26.

PMID:
29946869
6.
7.

Correction: Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.

Kanomata N, Matsuura S, Nomura T, Kurebayashi J, Mori T, Kitawaki J, Moriya T.

PLoS One. 2017 Aug 8;12(8):e0183202. doi: 10.1371/journal.pone.0183202. eCollection 2017.

8.

Cost analysis of leuprorelin acetate in Japanese pre-menopausal breast-cancer patients: comparison between 6-month and 3-month depot formulations.

Goto R, Uda A, Hiroi S, Iwasaki K, Takashima K, Kurebayashi J.

J Med Econ. 2017 Nov;20(11):1163-1169. doi: 10.1080/13696998.2017.1364647. Epub 2017 Aug 16.

PMID:
28782387
9.

Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.

Kanomata N, Matsuura S, Nomura T, Kurebayashi J, Mori T, Kitawaki J, Moriya T.

PLoS One. 2017 May 10;12(5):e0177439. doi: 10.1371/journal.pone.0177439. eCollection 2017. Erratum in: PLoS One. 2017 Aug 8;12 (8):e0183202.

10.

Anti-cancer stem cell activity of a hedgehog inhibitor GANT61 in estrogen receptor-positive breast cancer cells.

Kurebayashi J, Koike Y, Ohta Y, Saitoh W, Yamashita T, Kanomata N, Moriya T.

Cancer Sci. 2017 May;108(5):918-930. doi: 10.1111/cas.13205. Epub 2017 Apr 27.

11.

Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.

Koike Y, Ohta Y, Saitoh W, Yamashita T, Kanomata N, Moriya T, Kurebayashi J.

Breast Cancer. 2017 Sep;24(5):683-693. doi: 10.1007/s12282-017-0757-0. Epub 2017 Jan 31.

PMID:
28144905
12.

Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity.

Shi G, Yoshida Y, Yuki K, Nishimura T, Kawata Y, Kawashima M, Iwaisako K, Yoshikawa K, Kurebayashi J, Toi M, Noda M.

Oncotarget. 2016 Dec 13;7(50):82158-82169. doi: 10.18632/oncotarget.8620.

14.

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.

Duquette M, Sadow PM, Husain A, Sims JN, Antonello ZA, Fischer AH, Song C, Castellanos-Rizaldos E, Makrigiorgos GM, Kurebayashi J, Nose V, Van Hummelen P, Bronson RT, Vinco M, Giordano TJ, Dias-Santagata D, Pandolfi PP, Nucera C.

Oncotarget. 2015 Dec 15;6(40):42445-67. doi: 10.18632/oncotarget.6442.

15.

Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011.

Kurebayashi J, Miyoshi Y, Ishikawa T, Saji S, Sugie T, Suzuki T, Takahashi S, Nozaki M, Yamashita H, Tokuda Y, Nakamura S.

Breast Cancer. 2015 May;22(3):235-44. doi: 10.1007/s12282-015-0599-6. Epub 2015 Mar 11.

PMID:
25758809
16.

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.

Shiba E, Yamashita H, Kurebayashi J, Noguchi S, Iwase H, Ohashi Y, Sasai K, Fujimoto T.

Breast Cancer. 2016 May;23(3):499-509. doi: 10.1007/s12282-015-0593-z. Epub 2015 Feb 6.

17.

Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.

Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Moriya T.

Breast Cancer. 2016 May;23(3):425-36. doi: 10.1007/s12282-014-0580-9. Epub 2015 Jan 1.

PMID:
25552385
18.

A case of adenomatous goiter involving diffuse, acute, and painful thyroid enlargement after fine-needle aspiration cytology.

Shimo T, Tanaka K, Ogata R, Saito W, Ohta Y, Koike Y, Yamashita T, Yamamoto Y, Kurebayashi J.

Case Rep Endocrinol. 2014;2014:284912. doi: 10.1155/2014/284912. Epub 2014 Sep 3.

19.

The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy.

Kim SJ, Masuda N, Tsukamoto F, Inaji H, Akiyama F, Sonoo H, Kurebayashi J, Yoshidome K, Tsujimoto M, Takei H, Masuda S, Nakamura S, Noguchi S.

Cancer Lett. 2014 Dec 28;355(2):217-23. doi: 10.1016/j.canlet.2014.08.042. Epub 2014 Sep 10.

PMID:
25218592
20.

2013 clinical practice guidelines (The Japanese Breast Cancer Society): history, policy and mission.

Mukai H, Noguchi S, Akiyama F, Inaji H, Iwase H, Horiguchi J, Kurebayashi J, Hirata K, Toi M, Kurosumi M, Kohno N, Nishimura R, Nakamura S, Imoto S, Iwase T, Endo T, Saeki T, Ogawa Y, Ito Y, Tokuda Y, Ikeda T.

Breast Cancer. 2015 Jan;22(1):1-4. doi: 10.1007/s12282-014-0550-2. Epub 2014 Jul 24. No abstract available.

PMID:
25056934
21.

[I. Predict factor for hormone sensitivity and resistance].

Kurebayashi J.

Gan To Kagaku Ryoho. 2013 Dec;40(13):2500-4. Japanese. No abstract available.

PMID:
24422236
22.

Aberrantly methylated genes in human papillary thyroid cancer and their association with BRAF/RAS mutation.

Kikuchi Y, Tsuji E, Yagi K, Matsusaka K, Tsuji S, Kurebayashi J, Ogawa T, Aburatani H, Kaneda A.

Front Genet. 2013 Dec 5;4:271. doi: 10.3389/fgene.2013.00271. eCollection 2013.

23.

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.

Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.

Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.

PMID:
23749689
24.

Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma: comparison with female breast carcinoma.

Takagi K, Moriya T, Kurosumi M, Oka K, Miki Y, Ebata A, Toshima T, Tsunekawa S, Takei H, Hirakawa H, Ishida T, Hayashi S, Kurebayashi J, Sasano H, Suzuki T.

Horm Cancer. 2013 Feb;4(1):1-11. doi: 10.1007/s12672-012-0126-6. Epub 2012 Oct 18.

PMID:
23096432
25.

Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.

Kurebayashi J, Kanomata N, Shimo T, Yamashita T, Aogi K, Nishimura R, Shimizu C, Tsuda H, Moriya T, Sonoo H.

Breast Cancer. 2014 Mar;21(2):214-22. doi: 10.1007/s12282-012-0380-z. Epub 2012 Jun 12.

PMID:
22689016
26.

[A pilot study of the reduced effects of adverse events caused by oral morphine and oxycodone after rotating to fentanyl patch in patients with metastatic breast cancer].

Ikeda M, Sonoo H, Kurebayashi J, Oota Y, Fujii S, Shimo T, Mizutou A, Seki M, Saitou W, Yamashita T, Koike Y, Yamamoto Y, Shiiki S, Nakashima K, Tanaka K, Nomura T, Kubo S.

Gan To Kagaku Ryoho. 2012 Apr;39(4):599-603. Japanese.

PMID:
22504685
27.

Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.

Shimo T, Kurebayashi J, Kanomata N, Yamashita T, Kozuka Y, Moriya T, Sonoo H.

Breast Cancer. 2014 Jan;21(1):75-85. doi: 10.1007/s12282-012-0356-z. Epub 2012 Mar 28.

PMID:
22454224
28.

Analysis of clinical outcome of patients with poorly differentiated thyroid carcinoma.

Tanaka K, Sonoo H, Saito W, Ohta Y, Shimo T, Sohda M, Yamamoto Y, Kurebayashi J.

ISRN Endocrinol. 2011;2011:308029. doi: 10.5402/2011/308029. Epub 2011 Mar 29.

29.

Long-term outcome of hypofractionated radiotherapy to the whole breast of Japanese women after breast-conserving surgery.

Ishihara T, Yoden E, Konishi K, Nagase N, Yoshida K, Kurebayashi J, Sonoo H, Murashima N, Sasaki R, Hiratsuka J.

Breast Cancer. 2014 Jan;21(1):40-6. doi: 10.1007/s12282-012-0345-2. Epub 2012 Feb 22.

PMID:
22354451
30.

The cell cycle profile test is a prognostic indicator for breast cancer patients treated with postoperative 5-fluorouracil-based chemotherapy.

Kurebayashi J, Kanomata N, Kozuka Y, Moriya T, Kikukawa N, Kawasaki Y, Harada S, Tamura S, Nakayama S, Ishihara H, Noguchi S, Sonoo H.

Jpn J Clin Oncol. 2011 Jun;41(6):739-46. doi: 10.1093/jjco/hyr042. Epub 2011 Apr 27.

PMID:
21527410
31.

Clinicopathological significance of Y416Src and Y527Src expression in breast cancer.

Kanomata N, Kurebayashi J, Kozuka Y, Sonoo H, Moriya T.

J Clin Pathol. 2011 Jul;64(7):578-86. doi: 10.1136/jclinpath-2011-200042. Epub 2011 Apr 13.

PMID:
21490376
32.

Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer.

Sassa M, Hayashi Y, Watanabe R, Kikumori T, Imai T, Kurebayashi J, Kiuchi T, Murata Y.

Thyroid. 2011 May;21(5):511-7. doi: 10.1089/thy.2010.0295. Epub 2011 Mar 30.

PMID:
21449767
33.

[A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock].

Ikeda M, Sonoo H, Oota Y, Fujii S, Shimo T, Miyake A, Seki M, Nomura T, Yamamoto Y, Shiiki S, Nakashima K, Tanaka K, Kurebayashi J.

Gan To Kagaku Ryoho. 2010 Dec;37(13):2917-20. Japanese.

PMID:
21160270
34.
35.

Molecular morphological approach to the pathological study of development and advancement of human breast cancer.

Moriya T, Kanomata N, Kozuka Y, Hirakawa H, Kimijima I, Kimura M, Watanabe M, Sasano H, Ishida T, Ohuchi N, Kurebayashi J, Sonoo H.

Med Mol Morphol. 2010 Jun;43(2):67-73. doi: 10.1007/s00795-010-0504-5. Epub 2010 Aug 4. Review.

PMID:
20683691
36.

Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.

Vogel C, Chan A, Gril B, Kim SB, Kurebayashi J, Liu L, Lu YS, Moon H.

Jpn J Clin Oncol. 2010 Nov;40(11):999-1013. doi: 10.1093/jjco/hyq084. Epub 2010 Jun 11. Review.

37.

Nuclear cysteine cathepsin variants in thyroid carcinoma cells.

Tedelind S, Poliakova K, Valeta A, Hunegnaw R, Yemanaberhan EL, Heldin NE, Kurebayashi J, Weber E, Kopitar-Jerala N, Turk B, Bogyo M, Brix K.

Biol Chem. 2010 Aug;391(8):923-35. doi: 10.1515/BC.2010.109.

38.

Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur·uracil.

Osaki A, Mitsuyama S, Kurebayashi JI, Sonoo H, Nishimura R, Koga T, Murakami S, Ohno S.

Oncol Lett. 2010 Jan;1(1):45-49. Epub 2010 Jan 1.

39.

Predictive factors for anthracycline-based chemotherapy for human breast cancer.

Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kono S, Morimoto K, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S.

Breast Cancer. 2010 Apr;17(2):103-9. doi: 10.1007/s12282-009-0152-6. Epub 2009 Aug 6. Review.

PMID:
19657712
40.

Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.

Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T.

Breast Cancer. 2010 Apr;17(2):118-24. doi: 10.1007/s12282-009-0113-0. Epub 2009 May 23.

PMID:
19466512
41.

Preoperative dynamic lymphoscintigraphy predicts sentinel lymph node metastasis in patients with early breast cancer.

Nakashima K, Kurebayashi J, Sonoo H, Tanaka K, Ikeda M, Shiiki S, Yamamoto Y, Nomura T, Sohda M, Seki M, Miyake A, Moriya T, Sadahira Y, Mimura H, Fukunaga M.

Breast Cancer. 2010;17(1):17-21. doi: 10.1007/s12282-009-0123-y. Epub 2009 May 23.

PMID:
19466508
42.

[Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer].

Ikeda M, Kurebayashi J, Sonoo H, Oota Y, Fujii S, Shimo T, Miyake A, Seki M, Souda M, Nomura T, Yamamoto Y, Shiiki S, Nakashima K, Tanaka K.

Gan To Kagaku Ryoho. 2009 May;36(5):773-7. Japanese.

PMID:
19461176
43.

Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.

Kurebayashi J, Nukatsuka M, Sonoo H, Uchida J, Kiniwa M.

Cancer Chemother Pharmacol. 2010 Jan;65(2):219-25. doi: 10.1007/s00280-009-1024-7.

PMID:
19455332
44.

Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.

Kurebayashi J.

Breast Cancer. 2009;16(4):275-80. doi: 10.1007/s12282-009-0111-2. Epub 2009 May 1.

PMID:
19408071
45.

Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.

Tabuchi Y, Matsuoka J, Gunduz M, Imada T, Ono R, Ito M, Motoki T, Yamatsuji T, Shirakawa Y, Takaoka M, Haisa M, Tanaka N, Kurebayashi J, Jordan VC, Naomoto Y.

Int J Oncol. 2009 Feb;34(2):313-9.

PMID:
19148464
46.

The expression of monocyte chemotactic protein-1 in papillary thyroid carcinoma is correlated with lymph node metastasis and tumor recurrence.

Tanaka K, Kurebayashi J, Sohda M, Nomura T, Prabhakar U, Yan L, Sonoo H.

Thyroid. 2009 Jan;19(1):21-5. doi: 10.1089/thy.2008.0237.

PMID:
19072670
47.

[A case of paclitaxel and trastuzumab-resistant recurrent breast cancer with liver metastasis responding to S-1].

Nomura T, Sonoo H, Miyake A, Souda M, Yamamoto Y, Shiiki S, Ikeda M, Nakashima K, Tanaka K, Kurebayashi J.

Gan To Kagaku Ryoho. 2008 Sep;35(9):1607-10. Japanese.

PMID:
18799922
48.

[Bone-related events in breast cancer].

Kurebayashi J.

Clin Calcium. 2008 Apr;18(4):447-54. doi: CliCa0804447454. Review. Japanese.

PMID:
18379025
49.

[Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer].

Ikeda M, Kurebayashi J, Sonoo H, Miyake A, Nomura T, Yamamoto Y, Shiiki S, Nakashima K, Tanaka K.

Gan To Kagaku Ryoho. 2008 Feb;35(2):261-5. Japanese.

PMID:
18281762
50.

Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.

Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.

Cancer Lett. 2008 Jun 8;264(1):44-53. doi: 10.1016/j.canlet.2008.01.015. Epub 2008 Feb 15.

PMID:
18280644

Supplemental Content

Loading ...
Support Center